Research Nester released a report titled “VEGF Inhibitor Drugs Market: Global Demand Analysis & Opportunity Outlook 2028” which delivers detailed overview of the global VEGF inhibitor drugs market in terms of market by target, by inhibitor, by application, by distribution channel and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

VEGF inhibitors are the chemicals which restrict the functioning of VEGF or vascular endothelial growth factors. They prevent further cancer growth and eventually treat the condition effectively. VEGF inhibitor can be produced in the form of drugs and can be used as an effective cancer therapy. The market for VEGF inhibitor drugs is anticipated to grow at a CAGR of about 9% over the forecast period, i.e., 2020-2028. The market is segmented by target, by inhibitor, by application, by distribution channel and region. The target segment is further segmented into VEGF-A, VEGF-B, VEGF-C, VEGF-D and others, out of which, the market for VEGF-A is anticipated to hold the leading share in the VEGF inhibitor drugs market. This can be attributed to the property of VEGF-A for inducing angiogenesis as well as regulating the cell division in endothelial cells, which makes it responsible for a larger number of disorders such as cancers.

Based on region, the VEGF inhibitor drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. On the basis of this, the market in North America is estimated to lead the market with largest share globally as a result of increasing initiatives and investments by government and private entities that are promoting research and development of cancer therapies and treatments, including VEGF inhibitor drugs.

Increasing Cancer Cases Globally to Drive the Market Growth

As per the World Health Organization, cancer is the second leading cause of death worldwide. It was predicted to cause about 9.6 million deaths in 2018. Further, approximately 1 in every 6 deaths is caused as a result of cancer. As a result of this, the market for VEGF inhibitor drugs is predicted to significantly grow in the coming years. In addition to this, the growing elderly population all around the world is another factor estimated to contribute towards the increasing demand for novel therapies in the market. However, the high cost of VEGF inhibitor drugs, especially among the people belonging to middle and lower classes, it predicted to restrict the market growth in future.

This report also provides the existing competitive scenario of some of the key players of the global VEGF inhibitor drugs market which includes company profiling of Pfizer, Inc., Novartis AG, GlaxoSmithKline plc, Sanofi, AstraZeneca plc, Bristol-Myers-Squibb Company, Genentech, Inc. (Roche), Merck & Co., Inc., Bayer AG and Eli Lilly & Company. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global VEGF inhibitor drugs market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.